Anti-Dot1L/KMT4 Polyclonal Antibody for WB, ELISA - Q8TEK3

Core Product Specifications and Parameters

Biological Background: Dot1L/KMT4 Function and Localization

• Histone methyltransferase that specifically methylates 'Lys-79' of histone H3 (H3K79), with a strong preference for nucleosomal substrates over free histones. Related references: PMID:12123582 PMID:38503750 PMID:38129415
• Exhibits DNA-binding activity, which may contribute to its chromatin association. Related references: PMID:12628190 PMID:38503750
• In complex with MLLT3/AF9, mediates transcriptional repression of SCNN1A via H3K79 hypermethylation at the promoter (By similarity).
• Also known as DOT1-like protein, disruptor of telomeric silencing 1-like, and lysine N-methyltransferase 4 (KMT4).
• Localizes to both the nucleus and cytoplasm, indicating potential extranuclear roles.
• Contains a coiled-coil domain and repetitive elements; classified as a chromatin regulator and S-adenosyl-L-methionine-dependent methyltransferase.
• Post-translationally modified by phosphorylation and subject to alternative splicing, with disease-associated variants linked to intellectual disability.

Experimental Guidance and Technical Tips

• The immunogen corresponds to the N-terminal region (amino acids 1–250) of human Dot1L, which may be conserved across species, supporting cross-reactivity with rat and mouse.
• For Western blotting, a band around 165 kDa is expected; consider using a suitable gel percentage and transfer conditions for large proteins.
• Validate the antibody’s reactivity in your specific sample type and assay conditions, as performance may vary.
• For ELISA, titrate the antibody and include appropriate controls to assess specificity.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers and research laboratories with a seamless sourcing experience for IVD raw materials, including high-quality antibodies like this anti-Dot1L/KMT4 polyclonal antibody for chromatin modification studies. Our portfolio includes validated antibody pairs, optimized monoclonal and polyclonal antibodies, bulk ancillary reagents, and procurement of rare-target raw materials to accelerate your assay development from concept to clinic.